1. Home
  2. PRVA vs WVE Comparison

PRVA vs WVE Comparison

Compare PRVA & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Privia Health Group Inc.

PRVA

Privia Health Group Inc.

N/A

Current Price

$21.50

Market Cap

2.8B

Sector

Technology

ML Signal

N/A

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

N/A

Current Price

$13.50

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRVA
WVE
Founded
2007
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.4B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
PRVA
WVE
Price
$21.50
$13.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
16
Target Price
$30.50
$30.44
AVG Volume (30 Days)
653.1K
2.8M
Earning Date
01-01-0001
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$1,736,390,000.00
$3,704,000.00
Revenue This Year
$23.19
N/A
Revenue Next Year
$13.51
$15.93
P/E Ratio
$197.27
N/A
Revenue Growth
4.74
149.43
52 Week Low
$18.78
$5.28
52 Week High
$26.51
$21.73

Technical Indicators

Market Signals
Indicator
PRVA
WVE
Relative Strength Index (RSI) 39.93 50.35
Support Level $19.54 $12.53
Resistance Level $24.04 $14.56
Average True Range (ATR) 0.73 0.75
MACD 0.01 0.08
Stochastic Oscillator 27.50 47.56

Price Performance

Historical Comparison
PRVA
WVE

About PRVA Privia Health Group Inc.

Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: